Valneva’s Two-Front Test: Shigella Data and AGM Feedback Could Decide the Stock’s Direction

Valneva awaits Phase 2 Shigella vaccine data as stock nears €2.30. Aggressive cost-cutting aims to sustain operations; Lyme vaccine progress also in focus.

Investors in Valneva are bracing for a defining week. The stock is languishing near €2.30, more than 55% below its 52-week high of €5.16 set last August, and the pressure is mounting from two very different directions. On one side, the company must convince shareholders that its aggressive cost-cutting programme can sustain operations until late-stage pipeline milestones arrive. On the other, a potential scientific breakthrough from a Shigella vaccine candidate looms as the most immediate catalyst for a reversal.

The French biotech’s management will face investors at the BNP Paribas SMID Cap Conference in Paris on 24 June, followed by the annual general meeting in Lyon the next day. The backdrop is uncomfortable. First-quarter 2026 revenue slumped to €30.9 million from €49.2 million a year earlier, with product sales falling to €30.5 million. Valneva blamed the planned exit from third-party distribution and shifting delivery schedules to the US Department of Defense.

In response, the company launched a restructuring in April that aims to cut 10% to 15% of its global workforce and reduce operating costs by 25% to 35% versus 2025. Cash stood at €105.3 million on 31 March, and an April capital raise added €37.0 million. Still, the net loss for the first quarter widened to €32.1 million, and Valneva has trimmed its 2026 product revenue guidance from €145-€160 million to €135-€150 million, citing weaker demand for travel vaccines amid geopolitical uncertainty.

The Shigella wild card

The most powerful swing factor may come from the laboratory rather than the boardroom. Valneva is awaiting first Phase 2 data for its Shigella vaccine candidate S4V2, which targets the second most common cause of fatal diarrhoeal disease worldwide. No licensed vaccine is available in Western markets, and the US Food and Drug Administration has granted the programme Fast Track status. Analysts estimate annual peak sales potential above $500 million.

Positive results would hand Valneva the option to take over full development from its partner — a decision scheduled for the second half of this year. A negative readout, however, would likely send the stock straight toward its 52-week low of €2.13. Chart watchers note that the shares are trading just below the 50-day moving average of €2.46, with the next support at the multi-year trough.

Lyme vaccine progress adds a second storyline

Meanwhile, partner Pfizer is advancing the Lyme disease vaccine candidate LB6V. Phase 3 data have already shown roughly 74% efficacy, and Pfizer is preparing regulatory filings. Any formal submission would provide fresh upside for a stock that has shed 40% of its value since the start of 2026. The relative strength index at 40.7 indicates the shares are not oversold, but neither do they show upward momentum.

Macroeconomic data due this week could also influence sentiment. The European Commission publishes its consumer confidence indicator on 22 June, followed by INSEE’s French business climate index (last read at 94, below the long-term average of 100) on 23 June. The household confidence index, released on 25 June, stood at 84 in April. Weak readings would underscore the headwinds facing Valneva’s travel vaccine franchise.

What the AGM will not tell you

Shareholders will vote on the basis of 204.2 million voting rights as of 31 May 2026. The outcome of those resolutions is unlikely to move the needle as much as the message management sends to analysts in Paris. The key question is whether the cost savings are sufficient to bridge the company to clinical milestones — particularly the Lyme filing and the Shigella data — without another dilutive capital injection. For now, the stock sits in no-man’s land, waiting for a catalyst that could break the deadlock in either direction.